South Korea's Daewoong Pharmaceutical has entered a strategic partnership with China's Chime Biologics to develop and manufacture a biosimilar referencing Dupixent (dupilumab), one of the world's top-selling biologics. The collaboration marks Daewoong's full entry into the biosimilar sector as a long-term growth driver, leveraging Chime's end-to-end CDMO capabilities and AI-enabled development platform. For overseas medical aesthetics buyers, this signals expanding biosimilar supply options in the immunology space, which may eventually impact injectable therapy sourcing for dermatological conditions.
Partnership scope
Chime Biologics will provide end-to-end biosimilar development and commercialization services, including its AI-enabled Chime AI Platform and access to China's evolving bioprocess supply chain ecosystem through the Chime Innovation Alliance. Daewoong Pharmaceutical will leverage these resources to advance its dupilumab biosimilar candidate globally.
Market context
Dupixent, co-developed by Sanofi and Regeneron Pharmaceuticals, achieved approximately $17.8 billion in global sales in 2025, making it a blockbuster biologic and a prime target for biosimilar development. The immunology market is rapidly expanding, driven by demand for therapies treating atopic dermatitis and other Type 2 inflammatory diseases.
Strategic significance
This partnership represents Daewoong Pharmaceutical's full-fledged entry into the biosimilar sector as a key long-term growth engine. For overseas distributors and clinic buyers, the development could broaden the supply chain for affordable injectable immunology treatments, though regulatory approvals and market entry timelines remain to be seen.
Sourcing context
Chime Biologics, a China-based CDMO, brings extensive biosimilar development experience and a strong bioprocess supply chain network. This collaboration highlights the growing role of Chinese CDMOs in global biosimilar production, offering potential cost advantages and supply chain diversification for buyers seeking alternatives to Western manufacturers.
Source: Read the original report | Published: June 05, 2026